A breakthrough pancreatic cancer drug nearly doubled the survival rates of patients
According to the American Cancer Society, pancreatic cancer is one of the deadliest cancers in the United States. While the exact cause of most cases remains unknown, many are driven by genetic mutations that trigger uncontrolled cell growth in the pancreas.
In a breakthrough clinical trial, researchers targeted these mutations with a new drug called daraxonrasib. Patients who took the once-daily pill lived a median of 13.2 months, compared with 6.7 months for those who received chemotherapy alone.
In a separate study at the UCLA Health Jonsson Comprehensive Cancer Center, researchers found that daraxonrasib reduced the risk of death among patients with metastatic pancreatic cancer by 60%.
Even better: In addition to extending the survival rates of patients with pancreatic cancer, researchers are studying daraxonrasib across the board to see how it interacts with lung cancer, colorectal cancer, ovarian, and endometrial cancers.
For the first time, solar provided more electricity in the US than coal
In May 2026, solar supplied a record 12.8% of U.S. electricity, generating an all-time high total of 45.5 terawatt hours, while coal fell to 12.2%, its fourth-lowest monthly share ever.
Solar exceeded its output from May of last year by 17% and surpassed the previous record set in July last year. Experts say that record could be broken again in the coming summer months.
The milestone also came despite the federal government’s attempts to hinder and stop renewable energy growth.
*Some of these recommendations may include affiliate links, which means if you buy anything from this email, we may get something in return at no extra cost to you. (Thanks for your support!)
Do you think solar will continue to grow in the U.S.?
Need help? Contact us for assistance. We’ve got your back.
You received this email because you signed up for the Goodnewsletter from Good Good Good — or because you followed a recommendation from another newsletter or ordered a Goodnewspaper.
To stop receiving The Goodnewsletter, unsubscribe. To opt in or out of other emails from Good Good Good, manage your email settings. To stop receiving all emails from Good Good Good — which may potentially include paid subscriber-exclusive content — you can opt out entirely.